Our peptides are lyophilized (freeze-dried), making them shelf-stable for many weeks at room temperature
Our future success is highly dependent on our ability to timely complete successful clinical trials, obtain regulatory approval for, and then successfully commercialize our lead product candidate azelaprag and any future product candidates, which may never occur
Key risks of combining berberine and semaglutide include: Low blood sugar (hypoglycemia), particularly if you also use insulin or sulfonylureas Worsening GI symptoms such as nausea, cramping, bloating, diarrhea, or constipation Drug interactions from berberines effects on liver enzymes, which can change levels of other prescriptions These risks are the reason a clinician should review your full situation before you start the combo
Together, these peptides represent chemically stable, low-molecular-weight signaling molecules suitable for experimental use in cellular and preclinical research systems